Skip to main content
. 2020 Apr 17;12(4):995. doi: 10.3390/cancers12040995

Figure 1.

Figure 1

Study designs for the CUP, EAP and CAPRISTANA studies. a December 2010–May 2013; b July 2010–December 2014; c April 2012–June 2016. CUP: compassionate use program; EAP: expanded access program; mCRPC: metastatic castration-resistant prostate cancer; PRED: prednisone or prednisolone; Q3W: once every 3 weeks; QD: once daily.